Paul Choi
Stock Analyst at Goldman Sachs
(4.39)
# 1,249
Out of 4,690 analysts
376
Total ratings
55.9%
Success rate
9.3%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Reiterated: Buy | $105 | $74.13 | +41.64% | 12 | Aug 31, 2026 | |
| RGNX REGENXBIO | Maintained: Hold | $10 | $10.77 | -7.11% | 12 | Aug 25, 2026 | |
| HR Healthcare Realty Trust | Maintained: Hold | $14 | $19.38 | -27.77% | 1 | Aug 17, 2026 | |
| EWTX Edgewise Therapeutics | Rated: Hold | $32 → $36 | $44.17 | -18.50% | 4 | Aug 11, 2026 | |
| EXEL Exelixis | Maintained: Buy | $64 | $51.24 | +24.90% | 10 | Aug 5, 2026 | |
| URGN UroGen Pharma | Maintained: Hold | $44 → $48 | $48.22 | -0.46% | 25 | Aug 5, 2026 | |
| PTCT PTC Therapeutics | Maintained: Sell | $55 → $70 | $71.70 | -2.37% | 26 | Jul 30, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintained: Buy | $75 → $90 | $76.75 | +17.26% | 20 | Jul 30, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $300 | $248.50 | +20.72% | 27 | Jul 27, 2026 | |
| HCM HUTCHMED (China) | Rated: Hold | $19 → $14 | $12.20 | +14.75% | 20 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $95 → $90 | $31.63 | +184.54% | 4 | Jun 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $14.89 | +168.64% | 3 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $6 | $8.97 | -33.11% | 8 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $112 → $116 | $79.86 | +45.25% | 35 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $77 → $94 | $100.95 | -6.88% | 5 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $9.24 | +127.27% | 25 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $9.58 | - | 18 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $75 | $62.35 | +20.29% | 12 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $12 | $14.07 | -14.71% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $0.5 | $0.1542 | +224.25% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $5.79 | n/a | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.05 | n/a | 25 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.26 | n/a | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $67.34 | n/a | 1 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $133.40 | $19.19 | n/a | 1 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 | $6.26 | n/a | 5 | Jun 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $3.5 | $5.65 | n/a | 4 | Apr 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $7 | $8.83 | n/a | 8 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $9 | $13.28 | n/a | 5 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $17 | $115.96 | n/a | 3 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $5.05 | n/a | 1 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $150,000.00 | n/a | 2 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $135 | $152.72 | n/a | 4 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $18 → $20 | $73.02 | n/a | 5 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $135 → $165 | $120.16 | n/a | 2 | Nov 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $1,180.16 | n/a | 1 | Apr 7, 2017 |
Cytokinetics
Aug 31, 2026
Reiterated: Buy
Price Target: $105
Current: $74.13
Upside: +41.64%
REGENXBIO
Aug 25, 2026
Maintained: Hold
Price Target: $10
Current: $10.77
Upside: -7.11%
Healthcare Realty Trust
Aug 17, 2026
Maintained: Hold
Price Target: $14
Current: $19.38
Upside: -27.77%
Edgewise Therapeutics
Aug 11, 2026
Rated: Hold
Price Target: $32 → $36
Current: $44.17
Upside: -18.50%
Exelixis
Aug 5, 2026
Maintained: Buy
Price Target: $64
Current: $51.24
Upside: +24.90%
UroGen Pharma
Aug 5, 2026
Maintained: Hold
Price Target: $44 → $48
Current: $48.22
Upside: -0.46%
PTC Therapeutics
Jul 30, 2026
Maintained: Sell
Price Target: $55 → $70
Current: $71.70
Upside: -2.37%
Kiniksa Pharmaceuticals International,
Jul 30, 2026
Maintained: Buy
Price Target: $75 → $90
Current: $76.75
Upside: +17.26%
Ascendis Pharma
Jul 27, 2026
Maintained: Buy
Price Target: $300
Current: $248.50
Upside: +20.72%
HUTCHMED (China)
Jul 23, 2026
Rated: Hold
Price Target: $19 → $14
Current: $12.20
Upside: +14.75%
Jun 5, 2026
Maintained: Buy
Price Target: $95 → $90
Current: $31.63
Upside: +184.54%
May 14, 2026
Maintained: Buy
Price Target: $40
Current: $14.89
Upside: +168.64%
May 12, 2026
Maintained: Sell
Price Target: $6
Current: $8.97
Upside: -33.11%
May 8, 2026
Maintained: Buy
Price Target: $112 → $116
Current: $79.86
Upside: +45.25%
May 7, 2026
Maintained: Hold
Price Target: $77 → $94
Current: $100.95
Upside: -6.88%
May 6, 2026
Maintained: Buy
Price Target: $21
Current: $9.24
Upside: +127.27%
Apr 30, 2026
Maintained: Hold
Price Target: n/a
Current: $9.58
Upside: -
Mar 10, 2026
Maintained: Buy
Price Target: $75
Current: $62.35
Upside: +20.29%
Feb 25, 2026
Maintained: Sell
Price Target: $12
Current: $14.07
Upside: -14.71%
Feb 24, 2026
Downgraded: Hold
Price Target: $8 → $0.5
Current: $0.1542
Upside: +224.25%
Feb 11, 2025
Downgraded: Hold
Price Target: n/a
Current: $5.79
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $7.05
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $1.26
Upside: n/a
Jun 4, 2024
Maintained: Buy
Price Target: n/a
Current: $67.34
Upside: n/a
Nov 10, 2023
Maintained: Hold
Price Target: $133.40
Current: $19.19
Upside: n/a
Jun 28, 2023
Maintained: Buy
Price Target: $19
Current: $6.26
Upside: n/a
Apr 3, 2022
Downgraded: Hold
Price Target: $25 → $3.5
Current: $5.65
Upside: n/a
Nov 5, 2021
Maintained: Hold
Price Target: $8 → $7
Current: $8.83
Upside: n/a
Sep 22, 2021
Downgraded: Hold
Price Target: $12 → $9
Current: $13.28
Upside: n/a
Mar 4, 2021
Maintained: Buy
Price Target: $15 → $17
Current: $115.96
Upside: n/a
Nov 9, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $5.05
Upside: n/a
Aug 24, 2020
Maintained: Sell
Price Target: n/a
Current: $150,000.00
Upside: n/a
Jun 29, 2020
Downgraded: Hold
Price Target: $135
Current: $152.72
Upside: n/a
Mar 30, 2020
Upgraded: Hold
Price Target: $18 → $20
Current: $73.02
Upside: n/a
Nov 1, 2017
Maintained: Buy
Price Target: $135 → $165
Current: $120.16
Upside: n/a
Apr 7, 2017
Reiterated: Buy
Price Target: $90
Current: $1,180.16
Upside: n/a